AbbVie’s HCV Drug Cocktail Cures 99% in Trial
AbbVie Hepatitis C Combo Cures Almost All Patients in Late Trial
By Simeon Bennett March 03, 2014
AbbVie Inc. (ABBV:US)’s combination hepatitis C therapy cured almost all patients in a late-stage study, moving the company closer to marketing a treatment that will compete with Gilead Sciences Inc. (GILD:US) and Bristol-Myers Squibb Co. (BMY:US)
In a trial in 419 patients, AbbVie’s as-yet-unnamed drug cocktail cured 99 percent of those given it after 12 weeks, regardless of whether they added the older booster medicine ribavirin, the North Chicago-based company said today at the Conference on Retroviruses and Opportunistic Infections in Boston. AbbVie said it will seek U.S. approval this quarter.
Continue reading this entire article:
Decrease in the Number of People Living with HCV
Liver Care After Successful Hepatitis C Treatment